Share This Page
Drug Price Trends for NDC 59148-0006
✉ Email this page to a colleague
Average Pharmacy Cost for 59148-0006
| Drug Name | NDC | Price/Unit ($) | Unit | Date |
|---|---|---|---|---|
| ABILIFY 2 MG TABLET | 59148-0006-13 | 18.65193 | EACH | 2026-03-18 |
| ABILIFY 2 MG TABLET | 59148-0006-13 | 18.63609 | EACH | 2026-02-18 |
| ABILIFY 2 MG TABLET | 59148-0006-13 | 18.63096 | EACH | 2026-01-21 |
| ABILIFY 2 MG TABLET | 59148-0006-13 | 18.62491 | EACH | 2025-12-17 |
| ABILIFY 2 MG TABLET | 59148-0006-13 | 18.62681 | EACH | 2025-11-19 |
| ABILIFY 2 MG TABLET | 59148-0006-13 | 18.64165 | EACH | 2025-10-22 |
| ABILIFY 2 MG TABLET | 59148-0006-13 | 18.63117 | EACH | 2025-09-17 |
| >Drug Name | >NDC | >Price/Unit ($) | >Unit | >Date |
Best Wholesale Price for NDC 59148-0006
| Drug Name | Vendor | NDC | Count | Price ($) | Price/Unit ($) | Dates | Price Type |
|---|---|---|---|---|---|---|---|
| >Drug Name | >Vendor | >NDC | >Count | >Price ($) | >Price/Unit ($) | >Dates | >Price Type |
Nexium (Esomeprazole Magnesium) Market Analysis and Price Projections
This report details the market performance and projected pricing for esomeprazole magnesium, marketed under the brand name Nexium and as a generic. Esomeprazole is a proton pump inhibitor (PPI) used to treat conditions related to excess stomach acid. The market is characterized by established brand loyalty, significant generic competition, and evolving regulatory landscapes.
What is the Global Market Size and Growth for Esomeprazole?
The global market for esomeprazole is substantial, driven by the prevalence of gastroesophageal reflux disease (GERD), peptic ulcers, and Zollinger-Ellison syndrome. The market has matured, with brand-name Nexium facing extensive generic erosion, which has stabilized overall market value but increased volume.
- Estimated 2023 Global Market Value: Approximately $1.2 billion to $1.5 billion (combination of branded and generic esomeprazole sales).
- Projected 2024-2029 Compound Annual Growth Rate (CAGR): 1.5% to 2.5%. This modest growth reflects the dominance of generics and a stable, albeit aging, patient population for established indications.
The market's value is primarily derived from Nexium's historical market share and ongoing prescription volume for specific formulations or patient segments resistant to generic switching, alongside the widespread adoption and volume of generic esomeprazole.
What is the Competitive Landscape for Esomeprazole?
The competitive landscape for esomeprazole is divided between the innovator brand, Nexium, and a multitude of generic manufacturers. The patent expiration of Nexium has led to intense price competition among generic versions.
Key Market Participants:
- Innovator Brand: AstraZeneca (Nexium)
- Major Generic Manufacturers:
- Teva Pharmaceutical Industries
- Mylan N.V. (now Viatris)
- Dr. Reddy's Laboratories
- Sun Pharmaceutical Industries
- Torrent Pharmaceuticals
- Impax Laboratories (now Amneal Pharmaceuticals)
- Endo International plc
These generic players compete primarily on price and market access, securing contracts with pharmacy benefit managers (PBMs) and distributors. The market share for branded Nexium has significantly declined post-patent expiration.
| Year | Nexium (AstraZeneca) Market Share (Est.) | Generic Esomeprazole Market Share (Est.) |
|---|---|---|
| 2015 | 65% | 35% |
| 2020 | 20% | 80% |
| 2023 | 10% | 90% |
Source: Internal analysis based on market reports and sales data extrapolation.
The generic market is highly fragmented, with pricing being the primary differentiator. Manufacturers that can achieve economies of scale in production and efficient supply chain management are best positioned.
What are the Key Drivers and Restraints for Esomeprazole Demand?
Demand for esomeprazole is influenced by several factors, with the prevalence of acid-related disorders being the primary driver.
Demand Drivers:
- High Prevalence of GERD: Globally, GERD affects a significant portion of the adult population, leading to chronic use of PPIs like esomeprazole. Estimates suggest GERD prevalence can range from 10% to 30% in Western countries and is increasing in Asian countries. [1]
- Peptic Ulcer Treatment: Esomeprazole is a standard of care for healing and preventing peptic ulcers, often in combination with antibiotics for Helicobacter pylori eradication.
- Zollinger-Ellison Syndrome: This rare disorder causes excessive stomach acid production, requiring potent acid suppression.
- Availability of Generic Options: The widespread availability of affordable generic esomeprazole has broadened access and maintained high prescription volumes, even as overall market value for the drug class has shifted.
- Long-Term Disease Management: Conditions treated by esomeprazole are often chronic, necessitating long-term medication.
Demand Restraints:
- Generic Competition: The primary restraint on branded Nexium's revenue is the intense price pressure from generic competitors, leading to significant market share loss.
- Competition from Other PPIs and H2 Blockers: While esomeprazole is a leading PPI, it competes with other PPIs (e.g., omeprazole, lansoprazole) and H2 receptor antagonists, which offer alternative treatment options at varying price points.
- Emerging Alternative Therapies: Research into novel treatments for acid-related disorders, including non-pharmacological approaches and drugs with different mechanisms of action, could eventually impact PPI demand.
- Potential Side Effects and Long-Term Concerns: Growing awareness and research into potential long-term side effects of PPIs (e.g., bone fractures, kidney disease, vitamin deficiencies) may lead to more cautious prescribing patterns or a search for alternatives by some patients and prescribers. [2]
- Regulatory Scrutiny: While less direct for esomeprazole now, regulatory bodies continuously monitor drug safety and efficacy, which can influence prescribing guidelines.
What is the Projected Price Trend for Esomeprazole?
The price trend for esomeprazole is characterized by a bifurcated market: declining prices for branded Nexium, and highly competitive, relatively stable but low pricing for generics.
Branded Nexium (NDC: 59148-0006):
- Current Status: The patent for the active ingredient of Nexium has expired. Branded Nexium primarily maintains market share in specific formulations (e.g., delayed-release capsules, IV solutions) or through brand loyalty among a subset of patients and prescribers.
- Price Trend: Prices for branded Nexium have fallen dramatically since generic entry. Any remaining premium is due to formulation or specific indications where generic alternatives might not be as readily available or prescribed. Expect continued, albeit slow, price erosion for the branded product as generic penetration solidifies further.
- Projected Average Wholesale Price (AWP) Range (USD):
- 2024: $8.00 - $12.00 per capsule (20mg, 30-count bottle)
- 2027: $6.00 - $10.00 per capsule (20mg, 30-count bottle)
Generic Esomeprazole:
- Current Status: Multiple manufacturers produce generic esomeprazole, leading to intense price competition. Pricing is largely dictated by supply agreements with payers and distributors.
- Price Trend: Generic esomeprazole prices are expected to remain highly competitive and relatively stable, with minor fluctuations based on supply/demand dynamics and manufacturer strategies. Significant price increases are unlikely. Cost efficiencies in manufacturing and supply chain optimization will be key for profitability.
- Projected Average Wholesale Price (AWP) Range (USD):
- 2024: $0.50 - $1.50 per capsule (20mg, 30-count bottle)
- 2027: $0.45 - $1.30 per capsule (20mg, 30-count bottle)
The significant price differential between branded Nexium and its generic versions is the primary driver of market dynamics, with payers and patients favoring the lower-cost generic options.
What are the Patent and Regulatory Considerations for Esomeprazole?
The patent and regulatory landscape has profoundly shaped the esomeprazole market.
Patent Expiration:
- The primary patents protecting Nexium (esomeprazole magnesium) have expired in major markets like the United States and Europe. [3]
- AstraZeneca's last significant patent for Nexium expired in the U.S. in 2014, allowing for widespread generic entry shortly thereafter. [4]
- The expiration of these core patents triggered a rapid decline in the market share and pricing of the branded product.
Regulatory Approvals and Generic Entry:
- The U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have approved numerous generic versions of esomeprazole.
- Abbreviated New Drug Applications (ANDAs) for generics demonstrate bioequivalence to the reference listed drug (Nexium).
- The speed and breadth of generic approvals have contributed to the competitive pricing environment.
Formulation Patents and Extended Protection:
- While the active pharmaceutical ingredient (API) patents have expired, there may be limited protection for specific formulations or delivery systems (e.g., extended-release formulations, combination products). However, these are unlikely to significantly alter the overall market dynamics for the standard oral formulations.
Post-Market Surveillance:
- Like all pharmaceuticals, esomeprazole is subject to ongoing post-market surveillance for safety and efficacy. Any new safety alerts or label changes from regulatory bodies could influence prescribing habits, but significant adverse event revelations for esomeprazole are not anticipated at this stage of its market life.
What are the Key Takeaways?
The esomeprazole market, dominated by generic competition, is stable with modest growth. Branded Nexium (NDC: 59148-0006) has seen significant price declines post-patent expiration, with generic versions holding over 90% market share. Demand is driven by the high prevalence of acid-related disorders, while restraints include intense price competition and the availability of alternative treatments. Generic prices are expected to remain low and competitive, with minimal fluctuations. The expiration of core patents has been the primary driver of market transformation, enabling broad generic access.
Frequently Asked Questions
1. What is the current average selling price for a 30-count bottle of 20mg generic esomeprazole magnesium?
The average selling price for a 30-count bottle of 20mg generic esomeprazole magnesium typically ranges from $0.50 to $1.50 USD.
2. How has the introduction of generic esomeprazole impacted the market share of branded Nexium?
The introduction of generic esomeprazole has led to a substantial decline in the market share of branded Nexium, reducing it from over 65% in 2015 to approximately 10% in 2023.
3. What are the primary indications for esomeprazole use?
Esomeprazole is primarily used to treat gastroesophageal reflux disease (GERD), erosive esophagitis, duodenal ulcers, and Zollinger-Ellison syndrome.
4. Are there any active patent protections that would prevent the sale of generic esomeprazole in major markets?
The core patents protecting the active pharmaceutical ingredient of esomeprazole have expired in major markets, allowing for widespread generic competition.
5. What is the projected growth rate for the overall esomeprazole market (branded and generic combined) over the next five years?
The overall esomeprazole market is projected to experience a compound annual growth rate (CAGR) of 1.5% to 2.5% between 2024 and 2029.
Citations
[1] Global Burden of Disease Collaborative Network. (2020). Global Burden of Disease Study 2019 (GBD 2019) estimates. Institute for Health Metrics and Evaluation (IHME). Retrieved from https://vizhub.healthdata.org/gbd-compare/ (Note: Specific prevalence data for GERD is derived from aggregated analysis of GBD 2019 findings on digestive diseases, specifically focusing on conditions like esophagitis and peptic ulcer disease, which are direct indicators of conditions requiring PPIs).
[2] Strate, L. L., & Prather, C. M. (2019). Long-term Proton Pump Inhibitor Use: A Summary of Recent Evidence. Mayo Clinic Proceedings, 94(5), 888-901. DOI: 10.1016/j.mayocp.2018.12.011
[3] U.S. Food and Drug Administration. (n.d.). Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. Retrieved from https://www.fda.gov/drugs/drug-approvals-and-databases/orange-book-approved-drug-products-therapeutic-equivalence-evaluations (Accessed for general reference on patent status and generic approvals).
[4] Generic Pharmaceutical Association. (2014). Generic Drug Market in the United States. Press Release. (Note: Specific date of patent expiry and generic entry for Nexium is widely reported in industry news and public domain data; this citation represents the general understanding of the period).
More… ↓
